Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 14.36%17.63B | 6.53%4.17B | 7.41%4.73B | 14.36%4.35B | 32.95%4.38B | 25.67%15.41B | 30.26%3.91B | 24.80%4.41B | 29.40%3.8B | 17.94%3.29B |
Cost of revenue | 12.10%14.93B | 3.62%3.51B | 3.91%3.99B | 10.61%3.69B | 35.71%3.74B | 29.10%13.32B | 29.78%3.39B | 30.91%3.84B | 32.04%3.33B | 22.63%2.76B |
Gross profit | 28.72%2.7B | 25.40%656.35M | 30.92%747.57M | 41.19%658.5M | 18.80%639.19M | 7.58%2.1B | 33.51%523.4M | -5.02%571.03M | 13.23%466.38M | -1.41%538.03M |
Operating expense | 7.77%2.38B | 6.95%586.29M | 4.33%608.57M | 4.72%599.93M | 16.14%582.29M | 15.53%2.21B | 17.91%548.17M | 16.80%583.31M | 22.62%572.88M | 4.97%501.37M |
Staff costs | 11.45%965.7M | ---- | ---- | ---- | ---- | 17.03%866.51M | ---- | ---- | ---- | ---- |
Selling and administrative expenses | 3.80%979.24M | ---- | ---- | ---- | ---- | 4.55%943.41M | ---- | ---- | ---- | ---- |
-Selling and marketing expense | 2.75%929.14M | ---- | ---- | ---- | ---- | 3.85%904.27M | ---- | ---- | ---- | ---- |
-General and administrative expense | 28.00%50.1M | ---- | ---- | ---- | ---- | 23.79%39.14M | ---- | ---- | ---- | ---- |
Depreciation and amortization | 31.73%80.27M | ---- | ---- | ---- | ---- | 144.73%60.94M | ---- | ---- | ---- | ---- |
-Depreciation | 30.24%41.27M | ---- | ---- | ---- | ---- | 27.25%31.68M | ---- | ---- | ---- | ---- |
-Amortization | 33.34%39M | ---- | ---- | ---- | ---- | --29.25M | ---- | ---- | ---- | ---- |
Other operating expenses | 5.08%351.87M | ---- | ---- | ---- | ---- | 38.70%334.87M | ---- | ---- | ---- | ---- |
Operating profit | 403.62%324.54M | 382.78%70.06M | 1,231.94%139M | 155.00%58.58M | 55.19%56.9M | -356.23%-106.89M | 66.00%-24.78M | -112.07%-12.28M | -92.55%-106.5M | -46.19%36.66M |
Net non-operating interest income (expenses) | 73.09%-1.1M | 16.83%-1.03M | 82.52%-168K | 147.76%544K | 39.86%-445K | -415.30%-4.08M | -106.69%-1.24M | -62.33%-961K | -599.56%-1.14M | -532.75%-740K |
Non-operating interest income | 112.19%11.86M | 37.38%2.91M | 34.14%2.81M | 296.50%3.62M | 448.25%2.51M | 268.54%5.59M | 443.33%2.12M | 440.46%2.1M | 144.77%913K | 25.48%458K |
Non-operating interest expense | 34.04%12.95M | 17.41%3.94M | -2.52%2.98M | 49.90%3.08M | 146.74%2.96M | 318.86%9.66M | 239.57%3.36M | 212.04%3.06M | 1,315.17%2.05M | 517.53%1.2M |
Net investment income | 6.46%54.49M | 42.52%6.86M | 163.38%8.55M | -64.68%16.43M | 69.55%22.66M | -21.94%51.18M | -52.06%4.81M | -165.25%-13.49M | 118.06%46.5M | -1.25%13.36M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 138.43M | 0 | 0 | ||||
Income from associates and other participating interests | -76.49%-45.35M | -85.34%-18.51M | -19.02%-8M | -201.38%-13.11M | -23.55%-5.72M | -18.19%-25.7M | -835.30%-9.99M | 18.80%-6.72M | 44.19%-4.35M | -0.78%-4.63M |
Special income (charges) | 63.67%-39.56M | 154.18%6.28M | -60.88%12.35M | 33.50%-53.44M | 90.19%-4.76M | -1,073.88%-108.89M | -1,139.79%-11.59M | 2,439.74%31.57M | -2,401.86%-80.36M | -757.13%-48.51M |
Less:Restructuring and mergern&acquisition | -105.37%-2.41M | --0 | --0 | --0 | -105.37%-2.41M | --44.81M | --0 | --0 | --0 | --44.81M |
Less:Other special charges | 204.00%3.85M | 77.65%-705K | 453.52%2.01M | ---- | ---- | -2,192.09%-3.7M | -7,437.21%-3.16M | ---568K | ---- | ---- |
Less:Write off | -43.76%38.12M | -137.80%-5.58M | 53.68%-14.36M | -36.66%50.89M | 93.88%7.16M | 696.75%67.78M | 1,553.25%14.75M | -2,394.05%-31M | 2,316.22%80.34M | 150.05%3.7M |
Other non-operating income (expenses) | 5.36%43.37M | 25.10%9.25M | -21.22%13.16M | 11.16%12.11M | 43.46%8.85M | 11.16%41.16M | 7.55%7.39M | 90.41%16.71M | 37.24%10.89M | -54.11%6.17M |
Income before tax | 2,375.59%336.38M | 305.92%72.89M | 1,012.51%164.9M | 507.10%21.11M | 3,245.55%77.48M | -111.12%-14.78M | 39.57%-35.4M | -88.01%14.82M | 111.54%3.48M | -97.64%2.32M |
Income tax | 58.29%74.43M | -72.12%-8.82M | 2,057.19%47.72M | 101.27%49.76M | -156.43%-14.23M | -25.70%47.02M | 54.58%-5.13M | -95.01%2.21M | 2,434.28%24.72M | -19.44%25.21M |
Net income | 523.87%261.95M | 369.92%81.71M | 829.33%117.18M | -34.87%-28.65M | 500.55%91.71M | -188.70%-61.8M | 35.98%-30.27M | -84.09%12.61M | 26.92%-21.24M | -134.29%-22.9M |
Net income continuous operations | 523.87%261.95M | 369.92%81.71M | 829.25%117.18M | -34.85%-28.65M | 500.55%91.71M | -188.70%-61.8M | 35.99%-30.27M | -84.09%12.61M | 26.92%-21.24M | -134.29%-22.9M |
Noncontrolling interests | 40.38%14.6M | 38.21%13.88M | -90.49%94K | 115.01%95K | 527K | 10.4M | 10.05M | 988K | -633K | 0 |
Net income attributable to the company | 442.59%247.35M | 268.24%67.83M | 907.62%117.09M | -39.47%-28.74M | 498.24%91.18M | -203.62%-72.2M | 14.74%-40.32M | -85.34%11.62M | 29.10%-20.61M | -134.29%-22.9M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 442.59%247.35M | 268.24%67.83M | 907.62%117.09M | -39.47%-28.74M | 498.24%91.18M | -203.62%-72.2M | 14.74%-40.32M | -85.34%11.62M | 29.10%-20.61M | -134.29%-22.9M |
Gross dividend payment | ||||||||||
Basic earnings per share | 448.99%41.39 | 273.80%11.54 | 953.51%19.49 | -41.42%-4.78 | 510.30%15.14 | -206.27%-11.86 | 12.52%-6.64 | -85.43%1.85 | 27.62%-3.38 | -134.42%-3.69 |
Diluted earnings per share | 448.99%41.39 | 272.44%11.54 | 953.51%19.49 | -39.73%-4.78 | 510.30%15.14 | -206.27%-11.86 | 11.83%-6.6923 | -85.43%1.85 | 26.75%-3.4208 | -134.42%-3.69 |
Dividend per share | 3.33%15.5 | 6.67%8 | 0 | 0.00%7.5 | 0 | 0.00%15 | 0.00%7.5 | 0 | 0.00%7.5 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |